Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BelieveIT-201: Phase 2, Randomized Open-labeled Trial of TransCon (TC) TLR7/8 Agonist in Combination With Pembrolizumab or With TC IL-2 β/γ, or Pembrolizumab Alone as Neoadjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

NCT05980598 is registered in ClinicalTrials.gov with Ascendis Pharma A/S as lead sponsor.

NCT NCT05980598
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05980598 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BelieveIT-201: Phase 2, Randomized Open-labeled Trial of TransCon (TC) TLR7/8 Agonist in Combination With Pembrolizumab or With TC IL-2 β/γ, or Pembrolizumab Alone as Neoadjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
Lead sponsor
Ascendis Pharma A/S
Phase
Phase 2
Overall status
Terminated
Start date
September 29, 2023
Completion date
March 28, 2025
Enrollment
27 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck neoplasms